KALA BIO, Inc. - רווח לפני ריבית, מסים ופחת KALA

KALA BIO, Inc. (KALA) maintains stable sales based on the patent protection of its unique anti-inflammatory drops. The company's EBITDA reflects cash flow dynamics, where 0.00 determines the current value of the metric. Demand for such drugs remains independent of economic cycles, while the upcoming results of stem cell therapy clinical trials serve as a key growth driver.

This metric captures the actual cash flow from core operations, adjusted for depreciation and financial expenses, allowing for a real-time assessment of business liquidity. For KALA BIO, Inc. (KALA), which currently lacks sales, monitoring EBITDA_Co reflects the capital burn rate on R&D until patent protection is realized and premium pricing power is established for its ophthalmic drugs.